GET DAILY SIGNALSAveanna Healthcare Holdings (AVAH) Delivers Q3 2026 Beat as Revenue Climbs 11.8%
Key Takeaways
- Aveanna Healthcare Holdings reported third-quarter 2026 revenue of $695.5 million, up 11.8% year over year and above the consensus estimate of roughly $679.5 million.
- Adjusted earnings per share (EPS) came in at $0.23, beating the analyst consensus of $0.21 by $0.02.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 25.0% year over year to $100.1 million.
- Net income surged to $45.5 million, up from $14.1 million in the prior-year period.
- Despite the beat, AVAH shares fell roughly 6% in pre-market trading as investors weighed the company's raised full-year guidance against lofty expectations.
- The company increased its full-year 2026 revenue outlook to more than $2.695 billion and its adjusted EBITDA outlook to more than $374 million.
Earnings Context and Why It Matters
Aveanna Healthcare Holdings operates a diversified home care platform focused on pediatric and adult patients through private duty services, home health and hospice, and medical solutions. Its third-quarter 2026 results provide insight into demand trends for home and community-based care, caregiver labor conditions, and Medicaid reimbursement dynamics. The company has been advancing its preferred payer strategy to align capacity with higher-rate payers. Revenue growth has re-accelerated and margins have expanded, raising the question of whether Aveanna can maintain this momentum while handling leverage and a competitive labor market. From what I see, these results help gauge both the sustainability of the recovery and the reliability of full-year guidance.
Reported Results
For the third quarter ended October 3, 2026, Aveanna reported revenue of $695.5 million, an 11.8% increase from $621.9 million a year earlier and above the consensus estimate of approximately $679.5 million. Adjusted EPS of $0.23 beat the analyst consensus of $0.21, while diluted EPS was $0.20 (basic EPS was $0.21). Net income reached $45.5 million, up sharply from $14.1 million in the prior-year quarter.
Adjusted EBITDA increased 25.0% to $100.1 million. All three segments contributed to growth, led by Private Duty Services (PDS), which added $59.8 million in revenue, followed by Home Health & Hospice (HHH) at $9.7 million and Medical Solutions (MS) at $4.1 million. For the first nine months, revenue rose 13.7% to $2.014 billion, net income climbed to $127.4 million, and adjusted EBITDA reached $279.9 million. I also checked this using Tickeron’s AI Screener to compare AVAH against peers in the sector.
Market Reaction and Investor Sentiment
Despite a headline beat on both the top and bottom lines, AVAH shares declined roughly 6% in pre-market trading following the announcement. The pullback reflected a mixed reaction to guidance: Aveanna raised its full-year 2026 revenue outlook to more than $2.695 billion and its adjusted EBITDA outlook to more than $374 million, but the updated revenue midpoint aligned closely with the analyst consensus of about $2.69 billion. Some investors appeared to have expected stronger forward guidance after a run of positive momentum. The company's CEO, Jeff Shaner, framed the results as evidence of continued progress in the Aveanna Strategic Plan and sustained year-over-year growth.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether Aveanna can sustain double-digit revenue growth while preserving its margin expansion. The preferred payer strategy remains central to that story. By steering clinical capacity toward payers that offer enhanced reimbursement rates, Aveanna aims to support caregiver wages and improve hiring and retention, which in turn fuels volume growth.
Key factors to monitor include the pace of new preferred payer agreements across its PDS, HHH, and Medical Solutions segments, as well as state-level Medicaid rate decisions and any shifts in the caregiver labor market. Progress on rate integrity and cost-of-living adjustments will also influence margin trajectory in the quarters ahead.
On the balance sheet, Aveanna ended the quarter with about $197.8 million in cash and roughly $1.52 billion in total indebtedness, so leverage and interest costs remain important watchpoints. Free cash flow of $141.2 million for the first nine months offers a positive signal, but investors will want to see that cash generation persist as the company integrates growth and manages its debt load. Industry demand for home and community-based care remains strong, which supports the growth narrative, though execution on rates, staffing, and payer alignment will ultimately determine how much of that demand converts into durable profitability. I’m watching this closely as the preferred payer approach plays out.
Exploring AI Tools for Stock Analysis
One thing that stands out when reviewing names like this is how helpful AI-driven platforms can be for cross-checking data and spotting comparable opportunities. I’ve found Tickeron’s AI Screener particularly useful for filtering healthcare stocks by fundamentals, technical patterns, and performance metrics, which adds context beyond the earnings release itself. It allows for quick comparisons across industries and helps surface potential setups in a more structured way than manual review alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVAH sees MACD Histogram just turned negative
AVAH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 38 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AVAH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
AVAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on AVAH as a result. In 80 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
AVAH moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AVAH crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVAH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 141 of 177 cases where AVAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AVAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.043) is normal, around the industry mean (204.532). P/E Ratio (9.962) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.223) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement